|
||||||||||||||||||||||
|
|
Phase I Study of Adenoviral Vector Delivery of the Interleukin-12 Gene in Patients With Liver Metastases Secondary to Colorectal Cancer
Alternate Title Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
Objectives
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Patient Characteristics: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal Other
Expected Enrollment 36A total of 30-36 patients will be accrued for this study. Outline This is a dose-escalation study. Patients receive ultrasound-guided intratumoral injections of adenoviral vector-delivered interleukin-12 gene (ADV-hIL12) on day 1. Cohorts of 3-6 patients receive escalating doses of ADV-hIL12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at days 11, 15, 29, 43, and 57 and are then followed for survival thereafter. Trial Lead Organizations Mount Sinai Medical Center
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |